Место b-адреноблокаторов в лечении артериальной гипертонии, согласно мнению российских и европейских экспертов

1. Wiyonge CS, Bradley HA, Volmink J et al. Cochrane Database Syst Rev 2012; 11: CD002003.doi.
2. Bradley HA, Wiyonge CS, Volmink VA et al. How strong is the evidence for use of beta-blockers as first line therapy for hypertension? J Hypertens 2006; 24: 2131–41.
3. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
4. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165: 1410–9.
5. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews ofrandomised trials. Lancet 2003; 362: 1527–35.
6. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281–357.
7. Диагностика и лечение артериальной гипертензии (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов). Системные гипертензии. 2010; 7 (3): 5–26. / Recommendations for the management of arterial hypertension Russian Medical Society of Arterial Hypertension and Society of Cardiology of the Russian Federation. Systemic Hypertension. 2010; 7 (3): 5–26. [in Russian]
8. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Кардиологич. вестн. 2015; 1. / Klinicheskie rekomendatsii. Diagnostika i lechenie arterial'noi gipertonii. Kardiologich. vestn. 2015; 1. [in Russian]
9. Клиническая фармакология. Под ред. В.Г.Кукеса. Изд. 4-е. М.: ГЭОТАР-Медиа, 2008; с. 392–5. / Klinicheskaia farmakologiia. Pod red. V.G.Kukesa. Izd. 4-e. M.: GEOTAR-Media, 2008; s. 392–5. [in Russian]
10. Yusuf S, Hawken S, Ounpuu S et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937–52.
11. Mancia G, Laurent S, Agabiti-Rosei E et al. Re-appraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121–58.
12. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens 2009; 27: 923–34.
13. Кириченко А.А. Ишемическая болезнь сердца и контроль частоты сердечных сокращений. Consilium Medicum. 2015; 17 (5): 23–5. / Kirichenko A.A. Ischemic heart disease and heart rate monitoring. Consilium Medicum. 2015; 17 (5): 23–5. [in Russian]
14. Tocci G, Sciarretta S, Volpe M. Development of heart failure in recent hypertension trials. J Hypertens 2008; 26: 1477–86.
15. Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887–98.
16. McMurray JJV, Adamopoulos S, Anker SD et al. ESC Guidelines for diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2012; 33: 1787–847.
17. Rutten FH, Zuithoff NP, Halk F et al. Beta-Blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010; 170: 880–7.
18. MERIT-HF Study Group. Effects of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized International Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353 (9169): 2001–7.
19. Wikstrand J, Hjalmarson A, Waagstein F et al. MERIT-HF Study Group. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 2002; 40 (3): 491–8.
20. Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369–429.
21. Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2012; 33: 2719–3274.
22. Sandberg A, Blomqvist I, Jonsson UE, Lundborg P. Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol: A comparison with conventional tablets. Eur J Clin Pharmacol 1988; 33 (Suppl.): S9.
23. Oosterhuis B, Jonkman J, Zuiderwijk P, Sollie F. A pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK with a conventional slow release preparation. J Clin Pharmacol 1990; 30: S33–S38.
24. Sandberg A, Abrahamsson B, Regardh C-G et al. Pharmacokinetic and biopharmaceutic aspects of once daily treatment with metoprolol CR/ZOK: a review article. J Clin Pharmacol 1990; 30: S2–S16.
25. Lee Y-T, Liau C-S, Wong ECK et al. Pharmacokinetic and pharmacodynamic comparison of conventional and controlled release formulation of metoprolol in healthy Chinese subjects. Cardiovasc Drugs Ther 1989; 3 (4): 529–33.
26. Lucker P, Moore G, Wiselgren I et al. Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided doses. J Clin Pharmacol 1990; 30 (Suppl.): S17–S27.
27. Wieselgren I, Lundborg P, Sandberg A et al. Pharmacokinetic and pharmacodynamic evaluation of metoprolol controlled release (CR/ZOK) 50 mg in young subjects. J Clin Pharmacol 1990; 30: S28–S32.
28. Kronig B. Hertz Kreislauf 1990; 22: 224–9.
29. Nasr IA, Bouzamondo A, Hulot JS et al. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur Heart J 2007; 28: 457–62.
30. Swedberg K, Zannad F, McMurray JJ et al, EMPHASISHF Study Investigators. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASISHF (Eplerenone in Mild Patients Hospitalization And SurvIvalStudy in Heart Failure) study. J Am Coll Cardiol 2012; 59: 1598–603.
31. Schaer BA, Schneider C, Jick SS et al. Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study. Ann Intern Med 2010; 152: 78–84.
32. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet 2007; 369: 1208–19.
33. MERIT-HF Study Group. Effect of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure. MERIT-HF Study Group. JAMA 2000; 283: 1295–302.
34. Elliott W, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201–7.
35. Paravastu SC, Mendonca DA, da Silva A. Beta blockers for peripheral arterial disease. Eur J Vasc Endovasc Surg 2009; 38: 66–70.
36. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991; 151: 1769–76.
37. Camsari A, Arikan S, Avan C et al. Metoprolol, a beta–1 selective blocker, can be used safely in coronary artery disease patients with chronic obstructive pulmonary disease. Heart Vessels 2003; 18: 188–92.
38. Hedblad B, Wikstrand J, Jabzon L et al. Low dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001; 103: 1721–6.
39. Wiklund O, Hulthe J, Wikstrand J et al. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke 2002; 33 (2): 572–7.
40. Franzen D, Metha A, Seifert N et al. Effects of beta-blockers on sexual performance in men with coronary heart disease. A prospective, randomized and double blinded study. Int J Impot Res 2001; 13: 348–51.
41. Blood Pressure Lowering Treatment Trialists’ Collaboration. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J 2008; 29: 2669–80.
42. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 1986; 293: 1145–51.
43. Dahlof B, Lindholm LH, Hansson L et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281–5.
44. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: metaanalysis of randomized trials. BMJ 2008; 336: 1121–3.

________________________________________________

1. Wiyonge CS, Bradley HA, Volmink J et al. Cochrane Database Syst Rev 2012; 11: CD002003.doi.
2. Bradley HA, Wiyonge CS, Volmink VA et al. How strong is the evidence for use of beta-blockers as first line therapy for hypertension? J Hypertens 2006; 24: 2131–41.
3. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
4. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165: 1410–9.
5. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews ofrandomised trials. Lancet 2003; 362: 1527–35.
6. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281–357.
7. Recommendations for the management of arterial hypertension Russian Medical Society of Arterial Hypertension and Society of Cardiology of the Russian Federation. Systemic Hypertension. 2010; 7 (3): 5–26. [in Russian]
8. Klinicheskie rekomendatsii. Diagnostika i lechenie arterial'noi gipertonii. Kardiologich. vestn. 2015; 1. [in Russian]
9. Klinicheskaia farmakologiia. Pod red. V.G.Kukesa. Izd. 4-e. M.: GEOTAR-Media, 2008; s. 392–5. [in Russian]
10. Yusuf S, Hawken S, Ounpuu S et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937–52.
11. Mancia G, Laurent S, Agabiti-Rosei E et al. Re-appraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121–58.
12. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens 2009; 27: 923–34.
13. Kirichenko A.A. Ischemic heart disease and heart rate monitoring. Consilium Medicum. 2015; 17 (5): 23–5. [in Russian]
14. Tocci G, Sciarretta S, Volpe M. Development of heart failure in recent hypertension trials. J Hypertens 2008; 26: 1477–86.
15. Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887–98.
16. McMurray JJV, Adamopoulos S, Anker SD et al. ESC Guidelines for diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2012; 33: 1787–847.
17. Rutten FH, Zuithoff NP, Halk F et al. Beta-Blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010; 170: 880–7.
18. MERIT-HF Study Group. Effects of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized International Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353 (9169): 2001–7.
19. Wikstrand J, Hjalmarson A, Waagstein F et al. MERIT-HF Study Group. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 2002; 40 (3): 491–8.
20. Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369–429.
21. Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2012; 33: 2719–3274.
22. Sandberg A, Blomqvist I, Jonsson UE, Lundborg P. Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol: A comparison with conventional tablets. Eur J Clin Pharmacol 1988; 33 (Suppl.): S9.
23. Oosterhuis B, Jonkman J, Zuiderwijk P, Sollie F. A pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK with a conventional slow release preparation. J Clin Pharmacol 1990; 30: S33–S38.
24. Sandberg A, Abrahamsson B, Regardh C-G et al. Pharmacokinetic and biopharmaceutic aspects of once daily treatment with metoprolol CR/ZOK: a review article. J Clin Pharmacol 1990; 30: S2–S16.
25. Lee Y-T, Liau C-S, Wong ECK et al. Pharmacokinetic and pharmacodynamic comparison of conventional and controlled release formulation of metoprolol in healthy Chinese subjects. Cardiovasc Drugs Ther 1989; 3 (4): 529–33.
26. Lucker P, Moore G, Wiselgren I et al. Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided doses. J Clin Pharmacol 1990; 30 (Suppl.): S17–S27.
27. Wieselgren I, Lundborg P, Sandberg A et al. Pharmacokinetic and pharmacodynamic evaluation of metoprolol controlled release (CR/ZOK) 50 mg in young subjects. J Clin Pharmacol 1990; 30: S28–S32.
28. Kronig B. Hertz Kreislauf 1990; 22: 224–9.
29. Nasr IA, Bouzamondo A, Hulot JS et al. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur Heart J 2007; 28: 457–62.
30. Swedberg K, Zannad F, McMurray JJ et al, EMPHASISHF Study Investigators. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASISHF (Eplerenone in Mild Patients Hospitalization And SurvIvalStudy in Heart Failure) study. J Am Coll Cardiol 2012; 59: 1598–603.
31. Schaer BA, Schneider C, Jick SS et al. Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study. Ann Intern Med 2010; 152: 78–84.
32. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet 2007; 369: 1208–19.
33. MERIT-HF Study Group. Effect of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure. MERIT-HF Study Group. JAMA 2000; 283: 1295–302.
34. Elliott W, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201–7.
35. Paravastu SC, Mendonca DA, da Silva A. Beta blockers for peripheral arterial disease. Eur J Vasc Endovasc Surg 2009; 38: 66–70.
36. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991; 151: 1769–76.
37. Camsari A, Arikan S, Avan C et al. Metoprolol, a beta–1 selective blocker, can be used safely in coronary artery disease patients with chronic obstructive pulmonary disease. Heart Vessels 2003; 18: 188–92.
38. Hedblad B, Wikstrand J, Jabzon L et al. Low dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001; 103: 1721–6.
39. Wiklund O, Hulthe J, Wikstrand J et al. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke 2002; 33 (2): 572–7.
40. Franzen D, Metha A, Seifert N et al. Effects of beta-blockers on sexual performance in men with coronary heart disease. A prospective, randomized and double blinded study. Int J Impot Res 2001; 13: 348–51.
41. Blood Pressure Lowering Treatment Trialists’ Collaboration. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J 2008; 29: 2669–80.
42. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 1986; 293: 1145–51.
43. Dahlof B, Lindholm LH, Hansson L et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281–5.
44. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: metaanalysis of randomized trials. BMJ 2008; 336: 1121–3.

О.Д.Остроумова*1,2, В.М.Фомина1, Г.Н.Щукина1, Е.А.Смолярчук2

1 ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1;
2 ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
*ostroumova.olga@mail.ru

________________________________________________

O.D.Ostroumova*1,2, V.M.Fomina1, G.N.Shchukina1, E.A.Smoliarchuk2

1 A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1;
2 I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
*ostroumova.olga@mail.ru